CRISPR-Engineered Hookworms Produce Functional Antitoxin in Animal Hosts, Paving Way for Living Drug Factories
Key Insights
Researchers at Washington University School of Medicine achieved the first successful genetic modification of human hookworms using CRISPR/Cas9 (search), reported in Nature Communications.
Engineered hookworms produced an antibody neutralizing tetrodotoxin (search) and secreted it into the bloodstream of infected hamsters, achieving approximately 20% toxin neutralization.
The proof-of-concept study demonstrates a potential long-term drug delivery platform for chronic conditions including inflammatory bowel diseases, allergies, and obesity.
Researchers at Washington University School of Medicine in St. Louis have achieved the first successful genetic modification of the human hookworm, transforming the intestinal parasite into a living drug factory capable of producing and secreting a therapeutic protein into a host's bloodstream. The proof-of-concept study, published June 3 in Nature Communications, was funded by the U.S. Defense Advanced Research Projects Agency (DARPA (search)) and demonstrates that bioengineered hookworms can deliver functionally active molecules systemically.
"What we demonstrated here is that the concept works end to end — you can insert a gene, the worm produces the protein, the protein gets out of the worm, and it is functionally active in the host," said senior author Makedonka Mitreva, PhD, the Gordon R. Miller Professor in the John T. Milliken Department of Medicine's Division of Infectious Diseases at WashU Medicine.
A Configurable Chassis for Drug Delivery
The hookworm's appeal as a long-term drug production and delivery platform stems from its unique biology. When a controlled number of hookworm larvae are administered — either orally as a pill or through the skin like a lotion — the worms migrate to the small intestine and take up residence, often for years. Because hookworms cannot multiply inside the host, the infection remains at a fixed, controllable level. If clearance becomes necessary, a single dose of an oral anti-parasitic drug eliminates the worms within 24 hours.
Mitreva's team built on more than two decades of hookworm genomics research conducted at WashU Medicine to identify a viable site in the genome for gene insertion. A critical requirement was ensuring the insertion would not disrupt surrounding gene activity while prompting the worm to secrete the therapeutic protein outward into the host.
The technical hurdles were substantial. Gene-editing tools that work in other organisms had not been adapted for hookworms, and no one had previously achieved stable genetic modification in the species. The team collected eggs from the Ancylostoma ceylanicum hookworm and used electroporation — applying electricity to open temporary holes in cell membranes — to deliver the genetic payload, which included CRISPR/Cas9 (search) and instructions for making an antitoxin against tetrodotoxin (search).
Proof-of-Concept with Tetrodotoxin (search) Antitoxin
The antibody selected for this study neutralizes tetrodotoxin (search), a paralyzing and potentially lethal neurotoxin produced by pufferfish and other marine animals for which no antidote currently exists. DARPA (search)'s interest stems from the toxin's potential as a biochemical weapon and the need for countermeasures for soldiers in remote locations.
Blood collected from hamsters infected with the genetically modified hookworms partially neutralized tetrodotoxin (search), whereas blood from animals infected with unmodified worms showed no neutralizing capability. The engineered worms produced enough antibody fragments to neutralize approximately 20 percent of the toxin in a test-tube assay.
Mitreva noted that this level of neutralization, while significant, likely represents only a fraction of what the platform can ultimately deliver. Several components of what she calls a "configurable chassis" are still being optimized to increase the amount of therapeutic protein produced and secreted. Because the worm resides in the gut and a substantial portion of what it secretes remains there rather than entering the bloodstream, the researchers expect that concentrations of therapeutic molecules in the intestine may be substantially higher than what was detected in circulation, making the platform particularly suitable for gut-directed therapies.
Therapeutic Potential and Cautions
Gut inflammatory diseases, including Crohn's disease (search) and ulcerative colitis (search), and food allergies are among the conditions Mitreva sees as strong candidates for future development. Hookworms have already been studied as treatments for inflammatory bowel diseases based on evidence that the anti-inflammatory molecules the worms secrete can dampen immune responses driving those conditions. Diseases requiring small but sustained therapeutic concentrations, where compliance with repeated injections or infusions is a barrier, may also be well-suited to the platform.
"From that starting point, we can optimize the platform and think carefully about which diseases stand to benefit most from a delivery system that is continuous, targeted and long-lasting," Mitreva said. "That's a fundamentally different kind of pharmaceutical biofactory platform, and we think it opens possibilities that are very hard to achieve with any other platform."
However, significant work remains before human testing can be considered. Cornelis Hokke, a parasitic infectious diseases researcher at Leiden University Medical Center in the Netherlands who was not involved in the study, noted that the pufferfish toxin is so deadly that it may need to be completely neutralized for full protection. "Would [the antibody] then have had sufficient neutralizing capacity to save the hamster? The answer there might be no," he said.
Parasitologist Elissa Hallem of UCLA, also not involved with the work, emphasized that researchers need to engineer worms that can pass down the introduced genes for many generations to create a consistent product that could be prescribed to patients.
Safety Considerations
Although natural hookworm infection may cause only mild digestive symptoms in healthy adults, chronic infection with large numbers of hookworms can be dangerous for children, pregnant people, and malnourished or otherwise vulnerable individuals, leading to anemia, poor growth and development, pregnancy complications, and in extreme untreated cases, heart problems or death. This underscores the importance of keeping the infection strictly controlled for therapeutic use — possible because the worms cannot reproduce without spending part of their life cycle in soil.
Future studies will need to conduct rigorous safety evaluations before human use. Mitreva noted that biocontainment strategies, such as engineering the worms to be unable to produce eggs, are under consideration to protect hosts and their environments as the platform advances.
As Hokke observed, "It's moving a bit from science fiction to science."